SCHEMBL27038280

SCHEMBL27038280

CC(=O)Nc1nccc2cc(Cl)ncc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.40
▸ TYK2 P29597 2/20 0.40
▸ PTK2 Q05397 1/20 0.40
▸ SMARCA2 P51531 4/20 0.38
▸ SMARCA4 P51532 4/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ JAK1 P23458 1/20 0.36
▸ PIK3C3 Q8NEB9 3/20 0.36
▸ EGFR P00533 2/20 0.36
▸ MAT2A P31153 1/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ PRNP P04156 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27037364 0.80 TNF (0.38) JAK2TYK2MAT2AKDM4E
SCHEMBL19496864 0.76 SMN1; SMN2 (0.41) KDM4EMEN1KMT2A
SCHEMBL27038607 0.76 WNT3A (0.42) KDM4E
SCHEMBL30699267 0.76 WNT3A (0.42) KDM4E
SCHEMBL31473894 0.76 TNF (0.36) JAK2TYK2
SCHEMBL1690197 0.76 MEN1 (0.48) JAK2TYK2KDM4EMEN1KMT2A
SCHEMBL30698966 0.75 PIK3C3 (0.47) PTK2L3MBTL1PIK3C3EGFRKDM4E
SCHEMBL27037629 0.75 PIK3C3 (0.47) PTK2L3MBTL1PIK3C3EGFRKDM4E
SCHEMBL30698607 0.73 WNT3A (0.41) —
SCHEMBL30699087 0.73 PTK2 (0.50) JAK2TYK2PTK2L3MBTL1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 — — EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 — — CN disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 — — WO disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 — — US disclosed
WO-2023244788-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 JAK2 4/4885TYK2 1/4885PTK2 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback